Ponatinib in chronic myeloid leukaemia: ready for first-line?

被引：0
|
作者：
Breccia, Massimo [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
来源：
LANCET HAEMATOLOGY | 2015年 / 2卷 / 09期
关键词：
FOLLOW-UP; IMATINIB;
D O I：
10.1016/S2352-3026(15)00130-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E352 / E353
页数：2
相关论文
共 50 条
  • [21] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [22] Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy
    Khoury, Hanna J.
    Bixby, Dale L.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 568 - 576
  • [23] Second-Line Therapy for Patients With Chronic Myeloid Leukemia Resistant to First-Line Imatinib
    Lau, Anna
    Seiter, Karen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03) : 186 - 196
  • [24] Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib
    Angelopoulou, M. K.
    Asimakopoulos, J. V.
    Galani, Z.
    Levidou, G.
    Roumelioti, M.
    Vassilakopoulos, T. P.
    Korkolopoulou, P.
    Panayiotidis, P.
    BLOOD CANCER JOURNAL, 2016, 6 : e461 - e461
  • [25] First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
    Chen, Kang-Kang
    Du, Tai-Feng
    Wu, Ku-Sheng
    Yang, Wei
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3891 - 3910
  • [26] New strategies for the first-line treatment of chronic myeloid leukemia: Can resistance be avoided?
    Snead, Jennifer L.
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 : S107 - S117
  • [27] Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
    Giles, Francis J.
    Rosti, Gianantonio
    Beris, Photis
    Clark, Richard E.
    le Coutre, Philipp
    Mahon, Francois-Xavier
    Steegmann, Juan-Luis
    Valent, Peter
    Saglio, Giuseppe
    EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (06) : 665 - 673
  • [28] Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
    Haddad, Fadi G.
    Sasaki, Koji
    Nasr, Lewis
    Short, Nicholas J.
    Kadia, Tapan
    Dellasala, Sara
    Cortes, Jorge
    Nicolini, Franck E.
    Issa, Ghayas C.
    Jabbour, Elias
    Kantarjian, Hagop
    CANCER, 2024, 130 (19) : 3344 - 3352
  • [29] Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    LEUKEMIA RESEARCH, 2013, 37 (05) : 487 - 495
  • [30] Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Pandor, Abdullah
    Stevenson, Matt
    Stevens, John
    Martyn-St James, Marrissa
    Hamilton, Jean
    Byrne, Jenny
    Rudin, Claudius
    Rawdin, Andrew
    Wong, Ruth
    PHARMACOECONOMICS, 2018, 36 (08) : 903 - 915
12345